Kannikkatt Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 28 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
About Kannikkatt Pharmaceuticals
Kannikkatt Pharmaceuticals Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 March 1996 and has a history of 28 years and ten months. Its registered office is in Kottayam, Kerala.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Kannikkat Jose, Daisy Jose, and Alka Jose serve as directors at the Company.
Company Details
-
LocationKottayam, Kerala
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231KL1996PTC010177
-
Company No.
010177
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Mar 1996
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
What products or services does Kannikkatt Pharmaceuticals Private Limited offer?
Kannikkatt Pharmaceuticals Private Limited offers a wide range of products and services, including Chyawanprash, Dabur Chyawanprash, Herbal Soaps, Ayurvedic Soap.
Who are the key members and board of directors at Kannikkatt Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kannikkat Jose
|
Managing Director | 20-Mar-1996 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Daisy Jose
|
Director | 29-Jul-2009 | Current |
|
Alka Jose
|
Director | 29-Jul-2009 | Current |
Financial Performance of Kannikkatt Pharmaceuticals.
Kannikkatt Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kannikkatt Pharmaceuticals?
In 2017, Kannikkatt Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kannikkatt Pharmaceuticals?
Unlock and access historical data on people associated with Kannikkatt Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kannikkatt Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kannikkatt Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
